Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Maurer, Marcus ^a   Aberer, Werner ^b   Bouillet, Laurence ^c   Caballero, Teresa ^d   Fabien, Vincent ^e   Kanny, Gisèle ^f   Kaplan, Allen ^g   Longhurst, Hilary ^h   Zanichelli, Andrea ⁱ  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^e Shire Human Genetic Therapies ^*  (Switzerland)

^f UNIVERSITÉ DE LORRAINE   (France)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^h ROYAL LONDON HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANALGESIC AGENT; ANDROGEN; ANTACID AGENT; ANTIEMETIC AGENT; ANTIFIBRINOLYTIC AGENT; ANTIHISTAMINIC AGENT; ANXIOLYTIC AGENT; BRADYKININ B2 RECEPTOR; COMPLEMENT COMPONENT C1S INHIBITOR; CORTICOSTEROID; FRESH FROZEN PLASMA; ICATIBANT; SPASMOLYTIC AGENT;

ANGIONEUROTIC EDEMA; ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE DURATION; DRUG EFFECT; EARLY INTERVENTION; FEMALE; FLUID THERAPY; HUMAN; IMMUNOPROPHYLAXIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; SELF MEDICATION; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; BRADYKININ; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEREDITARY ANGIOEDEMA TYPES I AND II; HUMANS; MALE; PROSPECTIVE STUDIES; RECEPTOR, BRADYKININ B2; SELF ADMINISTRATION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84873508381     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053773     Document Type: Article

References (18)

1. Aberer W, (2012) Hereditary angioedema treatment options: The availability of new therapies. Ann Med 44: 523-529.
2. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, et al. (1998) Plasma bradykinin in angio-oedema. Lancet 351: 1693-1697.
3. Fields T, Ghebrehiwet B, Kaplan AP, (1983) Kinin formation in hereditary angioedema plasma: Evidence against kinin derivation from C2 and in support of 'spontaneous' formation of bradykinin. J Allergy Clin Immunol 72: 54-60.
4. Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, et al. (2007) Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clinical Immunol 119: 1497-1503.
5. Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, et al. (2010) Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema. N Engl J Med 363: 532-541.
6. Levi M, Choi G, Picavet C, Hack CE, (2006) Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 117: 904-908.
7. Kreuz W, Rusicke E, Martinez-Saguer I, Aygören-Pürsün E, Heller C, et al. (2012) Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema. Transfusion 52: 100-107.
8. Bork K, Meng G, Staubach P, Hardt J, (2005) Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 45: 1774-1784.
9. Bork K, Staubach P, Hardt J, (2008) Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angio-edema. Allergy 63: 751-757.
10. Cicardi M, Bork K, Caballero T, Craig T, Li HH, et al. (2012) Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 67: 147-157.
11. Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, et al. (2011) Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 107: 529-537.
12. Zhao Y, Qiu Q, Mahdi F, Shariat-Madar Z, Røjkjær R, et al. (2001) Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO production. Am J Physiol Heart Circ Physiol 280: H1821-H1829.
13. Kaplan AP, Austen KF, (1991) A prealbumin activator of prekallikrein II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med 133: 696-712.
14. Dunn JT, Kaplan AP, (1982) Formation and structure of human Hageman factor fragment. J Clin Invest 70: 627-631.
15. Joseph K, Tuscano TB, Kaplan AP, (2008) Studies of the mechanisms of bradykinin generation in hereditary angioedema plasma. Ann Allergy Asthma Immunol 101: 279-286.
16. Joseph K, Tholanikunnel B, Kaplan AP, (2002) Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc Natl Acad Sci 98: 896-900.
17. Cochrane CG, Revak SD, Wuepper KD, (1973) Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein. J Exp Med 138: 1568-1583.
18. Kaplan AP, Joseph K, (2010) The bradykinin-forming cascade and its role in hereditary angioedema. Ann Allergy Asthma Immunol 104: 193-204.